Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?

Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR.

Cancer Biol Ther. 2008 Jul;7(7):986-94. Epub 2008 Apr 21. Review.

2.

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q.

Mol Cancer Ther. 2008 Feb;7(2):286-96. doi: 10.1158/1535-7163.MCT-07-0483.

3.

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.

Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS.

BMC Cancer. 2008 Feb 6;8:43. doi: 10.1186/1471-2407-8-43.

4.

High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif.

Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE.

Cancer Res. 2007 Oct 1;67(19):9055-65.

5.

Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia.

Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ.

Mod Pathol. 2007 Dec;20(12):1238-44. Epub 2007 Sep 28.

6.

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.

Clin Cancer Res. 2007 Sep 1;13(17):5144-9.

7.

National failure to operate on early stage pancreatic cancer.

Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS.

Ann Surg. 2007 Aug;246(2):173-80.

8.

Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors.

Peng W, Anderson DG, Bao Y, Padera RF Jr, Langer R, Sawicki JA.

Prostate. 2007 Jun 1;67(8):855-62.

PMID:
17427200
9.

Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s.

Zugates GT, Peng W, Zumbuehl A, Jhunjhunwala S, Huang YH, Langer R, Sawicki JA, Anderson DG.

Mol Ther. 2007 Jul;15(7):1306-12. Epub 2007 Mar 20.

10.

Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies.

Kleeff J, Michalski CW, Friess H, B├╝chler MW.

Eur J Surg Oncol. 2007 Sep;33(7):817-23. Epub 2007 Feb 28. Review.

PMID:
17331695
11.
12.

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.

Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE.

Gastroenterology. 2006 Jun;130(7):2145-54.

PMID:
16762635
13.

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.

Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D.

Am J Clin Pathol. 2005 Dec;124(6):838-45.

PMID:
16416732
14.

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, Kreitman RJ, Pastan I.

Clin Cancer Res. 2005 Aug 15;11(16):5840-6.

15.

Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.

Peng W, Chen J, Huang YH, Sawicki JA.

Gene Ther. 2005 Nov;12(21):1573-80.

PMID:
16034457
16.

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA.

Cancer Cell. 2005 May;7(5):469-83.

17.

Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis.

Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N.

Pancreas. 2005 May;30(4):349-54.

PMID:
15841046
18.

Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy.

Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, Passineau MJ, Alvarez RD, Korokhov N, Curiel DT.

Gene Ther. 2005 Jan;12(2):187-93.

PMID:
15526007
19.

A polymer library approach to suicide gene therapy for cancer.

Anderson DG, Peng W, Akinc A, Hossain N, Kohn A, Padera R, Langer R, Sawicki JA.

Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33. Epub 2004 Nov 1.

20.

Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media.

Brody JR, Calhoun ES, Gallmeier E, Creavalle TD, Kern SE.

Biotechniques. 2004 Oct;37(4):598, 600, 602.

PMID:
15517972

Supplemental Content

Support Center